title: Rationale for combinatory chronic lymphocytic leukaemia treatment paradigms in the era of the B-cell receptor pathway and anti-apoptotic inhibitors: how do we mix, match, and move forward?
authors.affiliation: Division of Hematological Malignancies & Cellular Therapy, Department of Medicine, Duke University, Durham, NC, USA.
authors.forename: Danielle M
authors.initials: DM
authors.lastname: Brander
mesh_terms: D017209:Apoptosis; D001402:B-Lymphocytes; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell; D011947:Receptors, Antigen, B-Cell
chemical_list: D011947:Receptors, Antigen, B-Cell
keywords: B-cell receptor pathway inhibitors; anti-apoptotic inhibitors; chronic lymphocytic leukaemia treatment paradigms